Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid RCC
NCT00496587Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2007
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, gemcitabine, bevacizumab in sarcomatoid renal cell carcinoma (sRCC), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2007; status: completed.
02
Drugs
capecitabinegemcitabinebevacizumab
03
Conditions
sarcomatoid renal cell carcinoma (sRCC)
Beyond the preview
Go deeper on NCT00496587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00496587.